{"podcast":{"title":"Rheumnow Podcast","slug":"rheumnow-podcast-587987","podcast_index_feed_id":587987,"rss_url":"https://feed.podbean.com/rheumnow/feed.xml","website_url":"https://rheumnow.podbean.com","image_url":"https://pbcdn1.podbean.com/imglogo/image-logo/3681760/avatars-WU0yPZs9aq9zc0Tz-z65PkA-original.jpg","author":"Dr. Cush","episode_count":999,"summary":"Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com","last_synced_at":"2026-07-16T02:31:22.000703+00:00","page_url":"https://stenobird.com/podcast/rheumnow-podcast-587987"},"episode":{"title":"DERM on RheumNow Podcast (March 2026)","slug":"derm-on-rheumnow-podcast-march-2026","published_at":"2026-03-27T14:15:43+00:00","page_url":"https://stenobird.com/podcast/rheumnow-podcast-587987/derm-on-rheumnow-podcast-march-2026","show_page_url":"https://stenobird.com/podcast/rheumnow-podcast-587987","url":"https://rheumnow.podbean.com/e/derm-on-rheumnow-podcast-march-2026/","audio_url":"https://mcdn.podbean.com/mf/web/yc4qitq3mfn3uv79/DERM_on_RheumNow_Podcast_March_2026_5yv5x.mp3","summary":"This month: Multiple FDA regulatory decisions germane to dermatology, psoriasis and lupus; and Eosinophilic Fasciitis (EF) reminder and should you worry about fibromyalgia?Show Notes:1. FDA Approves Icotrokinra for Plaque Psoriasis The FDA approved an oral IL-23 inhibitor, icotrokinra (Icotyde), for use in moderate-to-severe plaque psoriasis in adults and children 12 years of age and older who are candidates for systemic therapy or phototherapy, according to a https://t.co/q5b3TceFHx2. FDA has approved secukinumab (Cosentyx) for use pediatric patients (aged 12yrs) with moderate to severe hidradenitis suppurativa https://t.co/oX4LGU16QP 3. FDA has accepted the supplemental biologics license application for use of interleukin-23 inhibitor tildrakizumab (Ilumya; Sun Pharma) in active psoriatic arthritis (PsA) in adults. https://t.co/cwqz9DoWsL https://t.co/ut0A4MwqW7 4. TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active PsA based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. https://t.co/a6rmortnoS 5.vUCB announced topline results of the BE-BOLD head-to-head study where bimekizumab (IL-17i) was superior to risankizumab (IL-23i) study; 553 active PsA in achieving an ACR50 response at 16 weeks. Enrolled PsA pts were either bilogic naïve or who had previous exposure to 1 TNFi 6. Retrospective TriNetX Network cohort study of adult PsA (N 123,031) pts, propensity- matched to non-PsA controls. PsA had signif higher CV morbidity: MACE (HR 1.74); mortality (HR 1.95); CHF (HR 1.96), MI (HR 1.71), & CVA (HR 1.49). bDMARDs reduced MACE (HR 0.95) & mortality (HR 0.92) vs csDMARDs https://t.co/bHrq9KpwBM 7. Prevalence…","meta_description":"This month: Multiple FDA regulatory decisions germane to dermatology, psoriasis and lupus; and Eosinophilic Fasciitis (EF) reminder and should you worry a…","key_points":[],"chapters":[],"topics":[],"duration_seconds":880,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/rheumnow-podcast-587987/episodes/derm-on-rheumnow-podcast-march-2026/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/rheumnow-podcast-587987/derm-on-rheumnow-podcast-march-2026.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}